Characterization of cytogenetic aberrations in feline vaccine-associated sarcoma

Vaccine-Associated Feline Sarcoma Task Force: Roundtable Discussion

The Vaccine-Associated Feline Sarcoma Task Force (VAFSTF) has served veterinarians, cats, and cat owners for nearly nine years. Initially designed to function for only three years, the VAFSTF members found a continuing need to address this issue utmost importance. Having fulfilled its mission to stimulate research and initiate preliminary changes in vaccination protocols designed to reduce the ...

Feline Vaccine-Associated Sarcomas

Association of germ-line polymorphisms in the feline p53 gene with genetic predisposition to vaccine-associated feline sarcoma.

A case-control study was conducted in order to investigate the association of polymorphisms in the genomic sequence of the feline p53 gene with a predisposition to vaccine-associated feline sarcoma (VAFS). In the study, 50 domestic short hair cats with a confirmed histopathologic diagnosis of VAFS were matched to disease-free controls (1:2) by age, sex, and breed. Cats from both the diseased (c...

Photodynamic hyperthermal chemotherapy with indocyanine green in feline vaccine-associated sarcoma

The anticancer effects of photodynamic hyperthermal chemotherapy (PHCT), which consists of a combination of indocyanine green photodynamic hyperthermal therapy and local chemotherapy, have previously been reported. The present study investigated the effect of PHCT in six cases of feline vaccine-associated sarcoma (FVAS) following conservative surgical resection. No recurrence was observed in th...

A retrospective analysis of radiation therapy for the treatment of feline vaccine-associated sarcoma.

We retrospectively evaluated predictive prognostic factors in 73 cats with vaccine-associated sarcoma given postsurgical curative (n = 46, most with clean margins) or coarse fractionated radiotherapy (n = 27, most with either macroscopic disease or dirty margins). The former animals displayed a median survival of 43 months and a median progression free interval (PFI) of 37 months, the latter re...